Papillomavirus

CarraShield Labs Issued Ground-breaking Patent for Anti-viral Gel Technology Used to Prevent HPV Infections

Wednesday, September 23, 2020 - 4:00pm

CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute.

Key Points: 
  • CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute.
  • The CarraShield gel technology opens up entirely new ways to help prevent HPV-induced cancers and warts above and beyond vaccines.
  • Current HPV vaccines only protect against up to 9 types of HPV virus out of over 200 HPV types.
  • The first product to contain CarraShield is Divine 9, a water-based personal lubricant used to help prevent HPV infections in women.

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Thursday, September 17, 2020 - 12:56am

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Key Points: 
  • ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.
  • But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."
  • Baum Hedlund Aristei & Goldmanis one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine .
  • Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022

Wednesday, September 16, 2020 - 4:45pm

During the period we delivered positive Phase 1b/2 results with TG4001, which have given us the confidence to progress the clinical development of this therapeutic vaccine against HPV-induced cancers.

Key Points: 
  • During the period we delivered positive Phase 1b/2 results with TG4001, which have given us the confidence to progress the clinical development of this therapeutic vaccine against HPV-induced cancers.
  • We intend to provide more detail on these positive Phase 1b/2 study results in the coming months.
  • Our oncolytic virus TG6002 showed positive initial data in a Phase 1 trial, indicating that it induces the production of a chemotherapy agent in the tumor.
  • Transgene intends to pursue the development of TG4001 and is actively working on the preparation of a confirmatory clinical study.

HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

Wednesday, September 16, 2020 - 12:45pm

It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.

Key Points: 
  • It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.
  • HPV-associated cancers, especially head and neck cancers, remain a significant health concern, as no curative therapies are currently available.
  • Human Papillomavirus, or HPV, is estimated to cause about 5% of the worldwide burden of cancers.
  • This includes approximately 99% of cases in cervical, up to 60% of head and neck, 70% of vaginal and 88% of anal cancers.

Microbix’s REDx™ Controls Attain Australian TGA Registration

Thursday, September 10, 2020 - 12:00pm

MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs) TGA registration of these REDx Controls & REDxFLOQ products by Microbixs distributor, R-Biopharm, enables it to offer these workflow controls to Australian clinical labs.

Key Points: 
  • MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs) TGA registration of these REDx Controls & REDxFLOQ products by Microbixs distributor, R-Biopharm, enables it to offer these workflow controls to Australian clinical labs.
  • This registration permits the sale of Microbixs positive and negative sample workflow controls in support of testing for active COVID-19 disease in liquid vial format (REDx Controls) and on room-temperature stable dried swabs (REDxFLOQ).
  • The registration also includes Microbixs liquid vial format REDx Controls positives for high-risk Human Papilloma Virus (HPV) types 16, 18, 45, and corresponding negative sample.
  • As whole-genome controls, Microbixs QAPs support test accuracy regardless of what variety of nucleic-acid sequences a test targets across the viral genome.

Vaxart, Inc. to Participate in September Virtual Investor Conferences

Thursday, September 3, 2020 - 1:00pm

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.

Key Points: 
  • A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.
  • Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19.
  • Vaxarts development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV).
  • For more information, please visit www.vaxart.com.

New treatment solution for U.S. cervical cancer patients now available for clinical use

Wednesday, August 19, 2020 - 3:44pm

Worldwide, there are 570,000 thousand new cervical cancer cases each year and 310,000 deaths from previously diagnosed cervical cancers, according to GLOBOCAN 2018 statistics.

Key Points: 
  • Worldwide, there are 570,000 thousand new cervical cancer cases each year and 310,000 deaths from previously diagnosed cervical cancers, according to GLOBOCAN 2018 statistics.
  • With the availability of Geneva, clinicians can now take advantage of a single gynecological applicator to treat most cervical cancer patients via intracavitary and/or interstitial brachytherapy treatment options.
  • "In the United States, Pap and HPV testing have been successful at continuously reducing the incidence of cervical cancer.
  • "Elekta is committed to innovation in the field of cervical cancer brachytherapy, which is a proven technique for improved overall survival.